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Background: Research has shown that treatments that solely addressed intimate partner violence (IPV) perpetration
were not very effective in reducing IPV, possibly due to neglecting individual differences between IPV perpetrators.
A large proportion of IPV perpetrators is diagnosed with co-occurring substance use disorders and it has been
demonstrated that successful treatment of alcohol dependence among alcohol dependent IPV perpetrators also led
to less IPV. The current study investigated the relative effectiveness of Integrated treatment for Substance abuse
and Partner violence (I-StoP) to cognitive behavioral treatment addressing substance use disorders including only
one session addressing partner violence (CBT-SUD+) among patients in substance abuse treatment who repeatedly
committed IPV. Substance use and IPV perpetration were primary outcome measures.
Method: Patients who entered substance abuse treatment were screened for IPV. Patients who disclosed at least 7
acts of physical IPV in the past year (N = 52) were randomly assigned to either I-StoP or CBT-SUD+. Patients in both
conditions received 16 treatment sessions. Substance use and IPV perpetration were assessed at pretreatment,
halfway treatment and posttreatment in blocks of 8 weeks. Both completers and intention-to-treat (ITT) analyses
were performed.
Results: Patients (completers and ITT) in both conditions significantly improved regarding substance use and IPV
perpetration at posttreatment compared with pretreatment. There were no differences in outcome between
conditions. Completers in both conditions almost fully abstained from IPV in 8 weeks before the end of treatment.
Conclusions: Both I-StoP and CBT-SUD+ were effective in reducing substance use and IPV perpetration among
patients in substance abuse treatment who repeatedly committed IPV and self-disclosed IPV perpetration. Since it is
more cost and time-effective to implement CBT-SUD+ than I-StoP, it is suggested to treat IPV perpetrators in
substance abuse treatment with CBT-SUD+.
Trial registration: ClinicalTrials.gov: NCT00847873
Keywords: Substance use disorders, Intimate partner violence, Perpetration, Treatment, Randomized controlled trial,
Comorbidity, Cognitive behavior therapy* Correspondence: F.L.Kraanen@uva.nl
1Department of Clinical Psychology, University of Amsterdam, Amsterdam,
The Netherlands
2Cognitive Science Center Amsterdam, University of Amsterdam, Amsterdam,
The Netherlands
Full list of author information is available at the end of the article
© 2013 Kraanen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Kraanen et al. BMC Psychiatry 2013, 13:189 Page 2 of 14
http://www.biomedcentral.com/1471-244X/13/189Background
Intimate partner violence (IPV) perpetration is highly
prevalent among substance abusers. Several studies dem-
onstrated that up to more than half of male and female
patients in substance abuse treatments committed at
least one act of physical IPV in the past year (e.g., [1-5];
Kraanen, Vedel, Scholing, Emmelkamp: Do specific sub-
stance use disorders or combinations of specific substance
use disorders predict past year intimate partner violence
in patients referred to substance abuse treatment?, submit-
ted). These figures are substantially higher than in the
normal population, where about 20% of the population
committed IPV in the past year [6]. Also, substance abuse
is overrepresented in male and female IPV perpetrators in
batterers’ treatment [7-13]. The relationship between
substance use (particularly alcohol use) and IPV received
increased attention over the past years. Several reviews
confirmed the association between alcohol use and IPV
(e.g., [14-16]). In addition, a number of studies demon-
strated that IPV perpetration in alcohol dependent
patients decreased substantially after successful treatment
for substance abuse (for reviews, see: [17,18]). These
results were found when substance abusers were treated
individually [4,19] as well as when participants had re-
ceived couples therapy [20-22]. Moreover, patients who re-
lapsed to alcohol use after successful alcohol use disorder
treatment were much more likely to relapse to IPV perpet-
ration than patients who abstained from alcohol [23,24].
Also, the use of illicit drugs (particularly cocaine and
cannabis) is connected to IPV perpetration (for reviews,
see: [15,25-27]). Presumably, different routes lead from
cocaine use and cannabis use to IPV perpetration [25]. For
cocaine it is hypothesized that its psychopharmacological
effects directly increase aggressive behavior (e.g., [28,29]),
whereas for cannabis it is assumed that irritability as a
result of withdrawal may lead to committing IPV [30]. To
our knowledge, it has not been studied yet whether suc-
cessful treatment of cannabis and cocaine use disorders in
patients who are referred for substance use treatment and
commit IPV, also reduces IPV perpetration.
Results described above indicate that successful treat-
ment of alcohol dependence in substance abusing IPV
perpetrators leads to reduced IPV perpetration. Par-
ticularly since there are no evidence-based treatments
for IPV perpetrators, these results are valuable. Several
meta-analyses examined the effectiveness of IPV treat-
ment; feminist psychoeducation (Duluth model) as well
as cognitive behavioral interventions were found to have
effect-sizes near zero [31,32] and were thus hardly effect-
ive in reducing IPV. There are some indications that
couples therapy aiming to reduce IPV may be promising
for specific couples and types of IPV [33,34], but it is
too early to draw firm conclusions. One major problem
of the early treatment studies on IPV is that mosttreatments were offered in a group format, followed a
one-size-fits-all approach, and did not take individual
characteristics of patients (such as substance use) into
account. Recently, several authors (e.g., [35-37]) claimed
that treatments for IPV should be more effectively tailored
to specific patient and couple characteristics.
Because treatment for alcohol use disorders is effective
in reducing IPV perpetration in alcohol abusing patients
referred for substance use treatment whereas IPV treat-
ment alone is not, several researchers called for integrat-
ing IPV and substance abuse treatment (e.g., [38-41]).
However, to date, only one randomized controlled trial
(RCT) has been carried out on the effectiveness of such
an integrated treatment. [42] conducted a pilot study
that compared the effectiveness of a combined alcohol
dependence / domestic violence group therapy based on
cognitive behavioral therapy (CBT) to a 12-step facilita-
tion group that did not address partner violence. Partici-
pants who received the combined treatment abstained
significantly more days from alcohol than participants in
the 12-step facilitation group and there was a trend for
participants in the combined treatment to engage in less
frequent IPV than participants in the 12-step group.
However, since there were differences in days of abstin-
ence between both conditions and alcohol use is possibly
causally related to IPV perpetration, it is necessary to
control for days of abstinence when assessing differences
between treatments in IPV perpetration. Further, in
[42]’s study the treatments for substance abuse in both
conditions differed from one another (i.e., CBT vs. 12-
step approach). Therefore, it was not possible to deter-
mine whether reductions in IPV were attributable to the
different treatment of substance abuse or to the focus on
IPV in the combined treatment. Also, some participants
had no actual intimate relationship. Although these par-
ticipants may benefit from the treatment in future rela-
tionships, it is not possible to measure reductions in IPV
perpetration when no partner is present. In addition,
only participants who were (also) diagnosed with alcohol
dependence were included, whereas research has dem-
onstrated a relationship between use of cocaine and can-
nabis and IPV perpetration as well. Besides, only men
were included whereas a substantial proportion of the
IPV perpetrators consist of women [43,44].
The current study compared CBT addressing both sub-
stance use disorders and IPV (Integrated treatment for
Substance abuse and Partner violence; I-STOP; [45,46]) to
CBT addressing only substance use disorders plus one
session addressing IPV for enhancing safety (CBT-SUD+).
The interventions addressing substance use were equal in
both conditions; CBT-SUD+ contained the same topics as
I-StoP regarding substance use but had more sessions to
address these topics. Further, only participants who actu-
ally were in an intimate relationship with the victim at the
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with other (primary) substance use disorders than alcohol
dependence could participate. The study was open for
male and female patients, and treatments were conducted
individually.
Aim of this study was to compare the effectiveness of
IPV perpetration between I-StoP and CBT-SUD+ on IPV
perpetration and reduction of substance abuse among
patients in substance abuse treatment who were involved
in a pattern of IPV perpetration. It was hypothesized that
1) participants’ substance use in both conditions would be
significantly reduced at posttreatment compared to pre-
treatment, 2) there would be no significant differences
between conditions regarding substance use at posttreat-
ment, 3) physical IPV perpetration would be significantly
reduced at posttreatment compared to pretreatment in
participants in both conditions, and 4) patients receiving
I-StoP would engage in less frequent IPV at posttreatment
compared to patients allocated to CBT-SUD+. Effects on
secondary outcome measures (verbal IPV, inflicted injur-
ies, general mental health, marital satisfaction, and treat-
ment satisfaction) were studied exploratory.
Methods
Participants
Participants were recruited from patients who sought
treatment at a substance abuse treatment facility (Jellinek)
in Amsterdam, the Netherlands, between August 1, 2009
and June 1, 2012. Patients were included if they 1)
disclosed 7 or more acts of physical IPV in the past year at
intake, 2) were diagnosed with abuse and / or dependence
of alcohol, cannabis and / or cocaine, 3) were in an intim-
ate relationship with the partner against whom they com-
mitted IPV, and 4) were triaged to outpatient treatment.
We aimed to include patients who committed at least 7
acts of IPV in the past year since the goal of the treatment
was to break a pattern of IPV perpetration in an enduring
relationship. Therefore, we intended not to include pa-
tients to whom IPV perpetration was an incident. Patients
who were involved in incidental IPV typically reported 2
or 3 acts of physical IPV (for example, they reported to
have pushed, grabbed, and slapped their partner). To se-
lect patients who were involved of a pattern of IPV perpet-
ration we decided to select a cutoff that was well above 3
and settled for a cutoff of 7. In addition, patients were
recruited on the basis of past year IPV, but IPV as treat-
ment outcome was assessed in blocks of 8 weeks. Another
reason to include only patients who were involved in a
pattern of IPV perpetration was to minimize the chance
that patients would report no acts of physical IPV at pre-
treatment and could thus not improve during treatment.
Finally, only patients who were able to follow outpatient
treatment were invited to participate because inpatients
were offered various other treatment modules besidessubstance abuse treatment, including social skills training
and emotion regulation treatment, which would overlap
with I-StoP. Patients were excluded if they 1) were diag-
nosed with crack cocaine or heroin abuse or dependence,
2) currently received treatment for other mental health
problems, 3) had insufficient knowledge of the Dutch
language to complete questionnaires, and 4) in case of
severe mental health problems (e.g., psychosis, suicidal
ideation) or cognitive disorders (e.g., Korsakoff ’s syn-
drome). Patients were excluded in case of crack cocaine
and/or heroin use disorders because these patients usu-
ally need more intensive treatment than outpatient
treatment. Initially it was aimed to include 100 partici-
pants in the current study.
Treatments
Two treatment protocols were developed for this study,
i.e., I-StoP and CBT-SUD+. Both treatments consisted of
16 sessions of 45 minutes and were ideally delivered
weekly to the participants. Treatments were conducted
individually, but the partner was invited to attend the
first session of both I-StoP and CBT-SUD+ in order to
check and enhance safety. I-StoP and CBT-SUD+ were
flexible treatment protocols, i.e., treatment could be
adjusted according to motivation and / or level of func-
tioning of the patient. Furthermore, sessions could be
modified in case of crisis, such as relapse to substance
use or IPV, or topics could be treated in different order
if relevant.
I-STOP
I-STOP concurrently addressed both substance abuse
and IPV perpetration. Substance abuse interventions
were based on evidence-based CBT protocols addressing
substance abuse adapted for use in The Netherlands
[47-50]; for a description of interventions, see [51]).
Interventions targeting IPV comprised CBT and were
based on the work of Dutton [52,53]. Motivational in-
terviewing techniques [54] were included to increase
participant’s motivation to change substance abuse and
stop IPV perpetration. Sessions primarily targeting IPV
and substance use were alternated. In addition, partici-
pants received a workbook containing psychoeducation,
weekly assignments that correspond to the central topic
of a session, and diary cards to daily register substance
abuse / craving and anger / perpetration of IPV. Thera-
pists were instructed to address both IPV and substance
abuse in each session by emphasizing anger / IPV regis-
trations if the central theme of a session was related to
substance abuse, and vice versa.
Each session followed the same structure: 1) address-
ing completed diary cards and assignments, 2) discussing
the main topic of the session, and 3) explaining the
assignment for the next session. I-StoP contained the
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was discussed with the patient and partner and the
couple was taught to take time-outs in case of high-risk
situations for IPV. It was important that the partner was
present in order to maximize the chance that the time
out was going to be successful and to minimize the risk
that the patient would use the tool abusively, for
example, to control the interaction with the partner (for
a more detailed description of the negotiated time-out
procedure, see [56]). In addition, the following topics
and interventions were addressed: explanation of the
treatment rationale, assessment of types of IPV that took
place in the relationship, assessment of pros and cons of
IPV and substance abuse, formulating treatment goals
regarding IPV (abstaining from IPV was the only adequate
treatment goal) and substance use (preferable abstinence,
but controlled substance use was also an accepted treat-
ment goal; see [51]), identifying self-control measures
to prevent substance use, making functional analyses of
substance use, anger management, coping with craving
and emotions that may lead to substance use, the asso-
ciation between thoughts, feelings, and behavior in re-
lation to substance use and IPV, communication skills,
and relapse prevention for IPV and substance use.
CBT-SUD+
CBT-SUD+ is a manualized, cognitive behavioral treat-
ment that can be considered treatment-as-usual for sub-
stance use treatment in The Netherlands. For ethical
reasons (checking and promoting safety), the first ses-
sion of CBT-SUD+ is the same as the first session of I-
STOP (i.e., a session addressing the ‘Cycle of Violence’
and time-out procedure with the partner). Sessions
followed the same structure as I-StoP-sessions. Further,
topics and interventions of CBT-SUD+ were the same as
I-STOP interventions addressing substance abuse. How-
ever, since CBT-SUD+ treatment consisted of 16 sessions
as well, there was twice as much time to discuss these
topics.
Therapists and treatment adherence
Five female social workers, who had received formal
training in CBT and motivational interviewing and who
had extensive experience in substance abuse counseling,
were trained in both treatment protocols. PE and FK su-
pervised therapists once every two weeks during su-
pervision sessions lasting 90 minutes. All patients were
discussed comprehensively during supervision and meet-
ings focused on adherence to treatment manuals and
preparation of future sessions.
Ethics and randomization
The study was registered at the clinical trials registry
(www.clinicaltrials.gov) (# NCT00847873) and was ap-proved by the Ethics Review Board of the University of
Amsterdam (2008-KP-466). Participants were randomly
assigned to either I-STOP or CBT-SUD+ using www.
randomization.com. Outcome of randomization was
written on cards and put in a closed envelope containing
participant numbers. Envelopes were handed to partici-
pants after completing pretreatment assessment.Measures
Outcome measures
IPV The Revised Conflict Tactics Scales (CTS2; [57])
was used to assess frequency and prevalence of IPV. The
CTS2 consists of 39 item pairs addressing both perpetra-
tion and victimization of a specific act of violence. An
example is: ‘I pushed my partner’ and ‘My partner pushed
me’. Answers are scored on a 7-point scale: 0 = never; 1 =
once; 2 = twice; 3 = 3–5 times; 4 = 6–10 times; 5 = 11–20
times and 6 =more than 20 times. The CTS2 comprises of
5 scales measuring different aspects of handling conflicts
between partners: 1) physical violence, 2) verbal violence,
3) sexual violence, 4) negotiation, and 5) injuries resulting
from IPV. Frequency scores of violent acts were calculated
by taking the average of the frequency range (e.g., 3–5
times = 4), as recommended by [57]. The CTS2 is world-
wide the scale that is most often used to measure the fre-
quency, type, and gravity of IPV. Previous research
showed that the CTS2 is reliable and valid for this goal
(e.g., [57-61]). As primary outcome measure, the physical
violence subscale was used; the verbal violence and injur-
ies scales were used to assess secondary treatment out-
comes. The CTS2 was administered pretreatment, halfway
treatment (after session 8), and posttreatment. The part-
ner was invited to complete the CTS2 pretreatment and
posttreatment as well. On every occasion IPV was assessed
with reference to the past 8 weeks.Substance use To assess substance use, the Timeline
Follow Back Interview (TLFB; [62]) and the Quick
Drinking Screen (QDS; [63]) were used. The TLFB is a
calendar-based method to assess frequency and quantity
of substance use and days of abstinence [64]. The TLFB
is often studied and most studies found the TLFB to be
a highly valid method to assess alcohol (e.g., [65,66]) and
drug use (for a review, see [67]). The instrument was ad-
ministered pre- en posttreatment to assess substance use
in 8 weeks prior to treatment and 8 weeks before the
end of treatment. In addition, the QDS was adminis-
tered. The QDS is a self-report instrument that contains
5 aggregate summary questions regarding alcohol use.
Data obtained by the QDS were found to be very similar
to data obtained by the TLFB [63,68,69]. The QDS was
modified to assess drug use as well. Participants were
asked about substance use in the past 8 weeks. The
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pretreatment, halfway treatment (after session 8), and
posttreatment, and assessed substance use in the past
8 weeks.
General psychopathology To assess general psycho-
pathology, the Brief Symptom Inventory (BSI; [70];
Dutch translation: [71]) was used. The total BSI score
provides an overall measure of severity of psychopath-
ology. Psychometric qualities of the BSI are good [72].
Participants completed the BSI at pre- and posttreatment;
the BSI assessed symptoms of psychopathology during the
past week.
Marital satisfaction The marital maladjustment-scale of
the Dutch version of the Maudsley Marital Questionnaire
(MMQ; [73]) was used to assess marital satisfaction. Psy-
chometric qualities are good (e.g., [73,74]). Participants
completed the MMQ at pre- and posttreatment.
Treatment satisfaction
Participants were asked at posttreatment to rate treat-
ment satisfaction on a scale from one to ten.
Clinical diagnoses and assessment of eligibility
Patient characteristics
The Measurements in the Addictions for Triage and
Evaluation (MATE; [75]) was used to assess patient char-
acteristics and to guide treatment allocation (i.e., alloca-
tion to inpatient or outpatient treatment).
IPV
The Jellinek Inventory for assessing Partner Violence
(J-IPV; [76]) was used to screen patients for past year
IPV perpetration. The J-IPV consists of 4 items; a positive
answer to at least one item is indicative for IPV perpetra-
tion. The J-IPV possesses good psychometric properties
to screen for IPV perpetration. In addition, the CTS2
(further named CTS2-screen to distinguish its purpose
here from the CTS2 when used as outcome measure)
[56] was administered to assess type and frequency of
acts of past year IPV perpetration; patients had to have
engaged in at least 7 acts of IPV in the past year to be
included in the study.
Axis-I disorders
Axis-I disorders were classified using the Structured
Clinical Interview for DSM-IV Axis-I Disorders (SCID-I;
[77]; Dutch translation: [78]).
Procedure
At the intake, the MATE was administered, followed by
the J-IPV. Patients who answered positive to one or
more J-IPV items were invited for a second intake,which involved administration of the SCID-I and CTS2-
screen. Participants who met inclusion criteria and were
willing to participate were scheduled for pretreatment
assessment. During this meeting, first, the purpose of
the study was explained and informed consent was
obtained. Then, the TLFB was administered and patients
consequently completed the BSI, the QDS, the CTS2,
and the MMQ. After that, participants were handed an
envelope containing the treatment condition they were
randomly assigned to (either I-StoP or CBT-SUD+) and
an appointment for participant and partner was scheduled
with one of the therapists. After that, treatment started.
After session 8, the therapist asked participants to
complete the modified QDS and the CTS2. After session
16, an appointment was scheduled for posttreatment
assessment, during which, consequently, the TLFB, the
BSI, the QDS, the CTS2, and the MMQ were completed.
There was no compensation for treatment participation or
completion of assessments by patients who completed
treatment; patients who dropped out from treatment re-




Demographics, current Axis-I disorder diagnoses, fre-
quency of past year IPV and number of dropouts were
compared between conditions using chi-square-tests for
dichotomous variables, and t-tests and Mann–Whitney
tests for normally and nonnormally distributed continu-
ous variables, respectively.
Treatment effects
For the analysis of treatment effects, both completers
and intention-to-treat (ITT) analyses were conducted.
For ITT analyses, the last observation carried forward
(LOCF) method was used. Patients were classified as
completer if they attended at least 75% of treatment ses-
sions. Patients were categorized as ITT if at least one
treatment session was attended. Two measures were
used to assess changes in substance use: days of abstin-
ence and the average quantity of substances that were
weekly used (since controlled substance use was also an
accepted treatment goal). Since participants used differ-
ent substances (measured on different scales, e.g. units
or grams) and -in several cases- more than one sub-
stance, it was necessary to calculate new (standardized)
Z-scores for substance use. First, pre- and posttreatment
quantities of 1) alcohol (mean standard units per week),
2) cannabis (mean grams per week), and 3) cocaine
(mean grams per week) that had been used by all patients
in the preceding 8 weeks were each displayed in a separate
column. Then, the data in each column were transformed
to Z-scores, after which the Z-scores in each column were
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for pretreatment and posttreatment separately, the Z-
scores for alcohol, cannabis, and cocaine were added up in
order to obtain a quantity-frequency summary measure of
the combined use of different substances at both pretreat-
ment and posttreatment. Days of abstinence and Z-scores
were calculated on the basis of the QDS (instead of the
TLFB) because QDS scores obtained halfway treatment
were of use for the LOCF procedure (the TLFB was
administered only at pre- and posttreatment). TLFB out-
comes were not further used. IPV outcomes at pretreat-
ment, halfway treatment and posttreatment were assessed
by calculating frequency scores of physical IPV (primary
outcome measure), verbal IPV, and injuries inflicted to the
partner within the preceding 8 weeks.
Pre- and posttreatment measures of substance use and
IPV were compared within treatments using one-tailed
paired samples t-tests for normally distributed values
and one-tailed Wilcoxon signed rank tests for non-
normally distributed values. ANCOVA’s using pretreat-
ment substance use / IPV as covariate were carried out
to assess between-treatment differences because initial
analyses showed a correlation between the pre- and
posttreatment scores on both substance use and IPV,
respectively. For a few ANCOVA’s the assumption of
normality was violated. However, since sample sizes were
roughly equal it was assumed that the F-statistic would
be relatively robust against violations of normality [79].
Further, Levene’s test was used to assess homogeneity of
variance. Finally, homogeneity of regression slopes was
assessed; for some analyses for the ITT sample this as-
sumption was violated. However, ANCOVA results are
relatively unaffected by violations of the assumption of
homogeneity of regression when group sizes are equal
[80-82]. Based on the above, there was no need to re-
frain from using ANCOVA’s.
Treatment effects–secondary outcome measures
Pre- and posttreatment BSI and MMQ scores to assess
overall psychopathology and marital satisfaction, respect-
ively, were compared within treatments using paired sam-
ples t-tests and Wilcoxon signed rank tests; ANCOVA’s
with pretreatment outcomes as covariate were performed
to assess differences in posttreatment BSI and MMQ
scores between treatments. An independent samples
Mann–Whitney test was used to compare treatment satis-
faction across both treatments.
Power analyses
We argued that to be clinically meaningful, the differ-
ence between pre- and posttreatment IPV should be
large. For example, a small decrease in IPV might be sta-
tistically significant, but if an IPV perpetrator abuses a
partner 3 times instead of 4 times in 8 weeks we did notconsider this of clinical importance. The same applied to
the difference between treatments. If, for example, IPV
would decrease only slightly more in the I-StoP condi-
tion than in the CBT-SUD+ condition, these results
would not match the effort needed to implement I-StoP
in routine clinical care. The number of participants that
were needed for a power of .80 was determined using
G*Power [83]. The analyses demonstrated that 12 partici-
pants per condition were necessary to detect a large differ-
ence within conditions (Cohen’s d > .80; [84]) at α = .05,
one-sided testing; 21 participants per condition were
needed to detect a large difference between conditions
including one covariate (i.e., a difference between pa-
tients who received I-StoP and patients who received
CBT-IPV+ after controlling for pretreatment values;
Cohen’s f > .40; [84]) at α = .05, one-sided testing.
Results
Participant characteristics
Figure 1 displays the CONSORT 2010 flow diagram of
participants from IPV screening through treatment com-
pletion. The final sample consisted of 52 patients who
were included in the treatment study; 27 and 25 partici-
pants were randomly assigned to I-StoP and CBT-SUD+
respectively. Table 1 displays demographics and clinical
characteristics of participants. There were no statistically
significant differences between participants receiving I-
StoP and participants receiving CBT-SUD+.
Retention
A total of 19 participants (36.5%) completed at least
75% of treatment sessions (I-StoP: N = 11 (40.7%);
CBT-SUD+: N = 8 (32.0%)). Dropout rates did not differ
significantly between I-StoP and CBT-SUD+ (p = .51).
Two out of 52 participants (1 in each condition) com-
pleted the pretreatment assessment but never started
treatment and were excluded from further analyses. Rea-
sons for dropout and other information regarding treat-
ment completion/dropout are displayed in Table 2. There
were no significant differences between conditions.
Primary outcomes
Substance use
Days of abstinence and substance use Z-scores of com-
pleters and ITT sample are displayed in Table 3.
In both treatment conditions the completers had been
significantly more days abstinent at posttreatment than
at pretreatment (I-StoP: Z (10) = −1.99; p = .02 (1-tailed);
SA: (t (7) = −4.17; p = .00). Comparable findings were
found on substance use Z-scores at posttreatment versus
pretreatment (I-StoP: Z (10) = −2.05; p = .02 (1-tailed);
CBT-SUD+: Z (7) = −2.37; p = .01 (1-tailed)). There were
no statistically significant differences between I-StoP and
SA in posttreatment days of abstinence and substance use
Figure 1 CONSORT 2010 flow chart of participant enrollment, randomization, and retention of the current study.
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analyses demonstrated similar results. Participants receiv-
ing I-StoP (Z = −2.13; p = .02; 1-tailed) as well as CBT-
SUD+ (Z = −3.08; p = .00; 1-tailed) had been significantly
more days abstinent at posttreatment than at pretreat-
ment. Also, participants allocated to I-StoP (Z = −1.97;
p = .02; 1-tailed) as well as CBT-SUD+ (Z = −2.72; p = .00;
1-tailed) had significantly lower substance use Z-scores at
posttreatment than at pretreatment. Again, there were no
differences between both conditions in days of abstinence
and substance use Z-scores after controlling for pretreat-
ment values.
IPV
Table 4 displays physical and verbal IPV perpetration
and injuries inflicted to the partner for both treatmentgroups, at pretreatment and posttreatment and for com-
pleters and ITT sample.
In both treatment conditions, the completers had com-
mitted significantly less physical IPV at posttreatment than
at pretreatment (I-StoP: Z (10) = −2.68; p = .00 (1-tailed);
CBT-SUD+: Z (7) = −2.37; p = .01 (1-tailed)). There were
no significant differences between both conditions re-
garding posttreatment physical IPV perpetration after
controlling for pretreatment physical IPV. ITT analyses
yielded similar results. I-StoP patients and CBT-SUD+
patients both had committed significantly less acts of
physical IPV at posttreatment (i.e., LOCF for dropouts)
than at pretreatment (I-StoP: Z = −2.32; p = .01 (1-tailed);
CBT-SUD+: Z = −2.87; p = .00 (1-tailed)). There were no
differences between the treatments after controlling for
pretreatment physical IPV perpetration.
Table 1 Demographics and clinical characteristics of patients at pretreatment
I-StoP CBT-SUD+ Overall
(N = 27) (N = 25) (N = 52) Between group analyses
N (%) N (%) N (%)
Gender
Male 19 (70.4) 17 (68.0) 36(69.2) X2 (1) = 0.03; p = .85
Female 8 (29.6) 8 (32.0) 16 (30.8)
Age (M, SD) 34.85 (9.87) 37.08 (8.87) 36.18 (9.29) t (50) = 0.43; p = .51
Relationship length (years) (M, SD) 5.08 (4.59) 7.94 (8.59) 6.48 (6.93) U = 270.00; p = .55
Current alcohol use disorder 22 (81.5) 19 (76.0) 41 (78.8) X2 (1) = 0.23; p = .63
Current cannabis use disorder 13 (48.1) 8 (32.0) 21 (40.4) X2 (1) = 1.41; p = .24
Current cocaine use disorder 6 (22.2) 9 (36.0) 15 (28.8) X2 (1) = 2.02; p = .16
Number of SUDs (M, SD) 1.48 (0.64) 1.44 (0.58) 1.46 (0.61) U = 330.50; p = .88
Current major depressive episode 4 (15.4) 6 (24.0) 10 (19.6) X2 (1) = 0.23; p = .63
Current panic disorder 1 (3.8) 0 (0.0) 1 (2.0) X2 (1) = 0.98; p = .32
Current social phobia 2 (7.7) 5 (20.0) 7 (13.7) X2 (1) = 1.63; p = .20
Current OCD 0 (0.0) 2 (8.0) 2 (3.9) X2 (1) = 2.17; p = .14
Current PTSD 1 (3.8) 4 (16.0) 5 (9.8) X2 (1) = 2.13; p = .15
Current GAD 1 (3.8) 0 (0.0) 1 (2.0) X2 (1) = 0.98; p = .32
Past year physical IPV perpetration 32.37 (47.62) 23.00 (23.20) 27.87 (37.84) U = 334.50; p = .96
Past year verbal IPV perpetration 69.19 (43.58) 52.24 (27.54) 61.04 (37.39) U = 2.96.00; p = .21
Past year sexual IPV perpetration (n = 51) 2.65 (9.90) 0.72 (2.51) 1.71 (7.28) U = 301.50; p = .48
Past year inflicted injuries (n = 51) 3.50 (3.96) 4.72 (6.63) 4.10 (5.42) U = 296.50; p = .59
Underwent clinical detoxification1 6 (24.0) 6 (25.0) 12 (24.5) X2 (1) = 0.01; p = .94
1 = clinical detoxification took place during the course of treatment if it appeared that patients could not obtain their treatment goal at home and lasted 1 week;
I-StoP = Integrated treatment for Substance abuse and Partner violence; CBT-SUD+ = substance abuse treatment; SUD = substance use disorder; OCD = obsessive
compulsive disorder; PTSD = posttraumatic stress disorder; GAD = generalized anxiety disorder; IPV = Intimate partner violence.
Table 2 Reasons for dropout and completion rates per condition
I-StoP CBT-SUD+ Overall
N = 25 N = 24 N = 49 Between group
analysesN (%) N (%) N (%)
Reasons for drop-out
Patients could not be contacted 9 (36.0) 10 (41.7) 19 (38.8) X2 (4) = 6.18; p = .19
Agreement treatment was no longer needed 3 (12.0) 0 (0.0) 3 (6.1)
Did not want treatment anymore 2 (8.0) 4 (16.7) 6 (12.2)
Needed different treatment 0 (0.0) 2 (8.3) 2 (4.1)
No. of sessions attended–ITT M (S.D.) 9.25 (6.54) 8.68 (5.59) 8.96 (6.02) U = 293.50; p = .89
No. of sessions attended–completers M (S.D.) 16.00 (0.00) 15.50 (1.41) 15.79 (0.92) U = 38.50; p = .68
No. of partners that attended first session 15 (60.0) 12 (50.0) 27 (55.1) X2 (1) = 0.50; p = .48
Relationship intact at posttreatment (completers) 24 (96.0) 24 (100.0) 48 (98.0) X2 (1) = .98; p = .32
Treatment duration–ITT (weeks) M (S.D.) 22.19 (14.43) 20.21 (12.44) 21.22 (13.39) t (47) = 0.51; p = .61
Treatment duration–completers (weeks) M (S.D.) 32.31 (12.53) 33.93 (6.80) 32.99 (10.22) U = 30.00; p = .25
Completed pretreatment assessment (t1) 25 (100.0) 24 (100%) 49 (100%) -
Completed halfway treatment assessment (t2) 11 (44.0%) 13 (54.2%) 24 (49.0%) X2 (1) = 0.51; p = .48
Completed posttreatment assessment (t3) 11 (44.0%) 8 (33.3%) 19 (38.8%) X2 (1) = 0.59; p = .44
No. = number; I-StoP = Integrated treatment for Substance abuse and Partner violence; CBT-SUD+ = substance abuse treatment.
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I-StoP = Integrated treatment for Substance abuse and Partner violence;
CBT-SUD+ = substance abuse treatment.
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verbal IPV perpetration among the completers (I-StoP:
t (10) = 1.99; p = .04 (1-tailed); CBT-SUD+: t (7) = 3.31;
p = .01 (1-tailed)), with no differences between the treat-
ments after controlling for pretreatment verbal IPV
perpetration. ITT analyses demonstrated that patients
receiving I-StoP did not commit significantly less verbal
IPV at posttreatment than at pretreatment (Z = −0.78;
p = .19; 1-tailed), whereas participants receiving CBT-
SUD+ did (Z = −2.76; p = .00; 1-tailed). However, after
controlling for pretreatment verbal IPV perpetration,
no differences between both treatments remained.
Finally, there was a non-significant trend that com-
pleters in both treatments had less often injured their
partner at posttreatment than at pretreatment (I-StoP:Table 4 IPV perpetration 8 weeks before pretreatment
assessment and 8 weeks before posttreatment








M (SD) M (SD) M (SD) M (SD)
























































IPV = intimate partner violence; I-StoP = Integrated treatment for Substance
abuse and Partner violence; CBT-SUD+ = substance abuse treatment.Z = −1.83; p = .06 (1-tailed); CBT-SUD+: Z = −1.89; p = .06
(1-tailed)); with no significant posttreatment difference
between both groups. ITT analyses demonstrated that
participants allocated to I-StoP had not injured their
partner significantly less often at posttreatment than at
pretreatment (Z =−1.11; p = .13; 1-tailed), whereas patients
receiving CBT-SUD+ did show a significant decrease in
injuries inflicted (Z = −2.38; p = .01; 1-tailed). However,
after controlling for pretreatment inflicted injuries, no
differences between treatments remained.Secondary outcome measures
Secondary outcome measures (general psychopathology,
marital satisfaction and treatment satisfaction) of com-
pleters and ITT sample are displayed in Table 5.
BSI scores reflecting psychopathology of participants in
both conditions were significantly lower at posttreatment
than at pretreatment for completers (I-StoP: t (9) =
2.92; p = .01 (1-sided); CBT-SUD+: t (7) = 3.97; p = .00))
as well as ITT (I-StoP: t (24) = 2.69; p = .01 (1-sided);
CBT-SUD+: t (23) = 2.69; p = .01 (1-sided)). There were
no differences between both conditions. MMQ scores,
reflecting marital satisfaction, had not significantly de-
creased (lower MMQ scores are associated with higher
marital satisfaction) within conditions, nor were there
any differences between the conditions for completers
as well as ITT analyses. Completers in both conditions
reported high rates of treatment satisfaction (on aver-
age over 8 out of ten). There were no differences in
treatment satisfaction between conditions.Table 5 Secondary outcome measures of completers



















































8.38 (1.16) 8.19 (0.65) - -
1 = the first five participants did not complete the MMQ since the instrument
was added to the assessment in a later phase of the study; 2 = in both
conditions, 8 participants evaluated treatment; BSI = brief symptom inventory;
MMQ =Maudsley marital questionnaire; I-StoP = Integrated treatment for
Substance abuse and Partner violence; CBT-SUD+ = substance
abuse treatment.
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This is the first study that compared individual inte-
grated CBT addressing both substance abuse and partner
violence (I-StoP) to a bona fide substance use treatment
as usual (i.e., CBT addressing substance abuse). Primary
aim of the present study was to compare the effective-
ness of I-StoP to substance use treatment as usual (with
one session addressing IPV added; CBT-SUD+) in redu-
cing physical IPV among patients referred for substance
abuse treatment who were involved in a pattern of IPV
perpetration. Analyses were conducted both on com-
pleters only and on all included patients (ITT sample).
As expected, both I-StoP and CBT-SUD+ were effective
in reducing substance use and no significant differences
between both conditions were found; completers and
ITT analyses yielded similar results. Further, in accordance
with expectations, both treatments led to a significant de-
crease in physical IPV perpetration from pretreatment to
posttreatment. However, contrary to expectations, I-StoP
had not been superior to CBT-SUD+ in decreasing IPV.
Again, the results on decrease in IPV were similar in
completers and ITT analyses. Regarding secondary out-
come measures, completers and ITT analyses showed
slightly different outcomes. Completers analyses revealed
a significant decrease in verbal IPV and inflicted injuries
and a significant improvement in general psychopath-
ology, with no differences between both treatments. In
contrast, ITT analyses demonstrated that I-StoP had not
led to less verbal IPV at posttreatment compared to
pretreatment, whereas CBT-SUD+ had. This difference
between conditions was significant. In addition, there
was a non-significant trend that CBT-SUD+ had been
effective in decreasing inflicted injuries, whereas I-StoP
had not. Further, even though marital satisfaction at
pretreatment was close to the maritally distressed range
[85], both treatments (completers and ITT) did not
improve marital satisfaction. Finally, completers in both
conditions reported high rates of treatment satisfaction.
Although I-StoP was not more effective in reducing
IPV than CBT-SUD+, the results of the current study
are promising. Patients who completed treatment hardly
engaged in IPV perpetration in the 8 weeks before treat-
ment completion (I-StoP: M = 0.82 and CBT-SUD+:
M = 0.38 acts of physical IPV perpetration at post-
treatment). Therefore, the decrease of IPV perpetration
after treatment completion was not only statistically
significant but also clinically relevant. Moreover, the
current study demonstrated that, on case level, patients
with cannabis and/or cocaine use disorders also decreased
IPV perpetration after substance abuse treatment. Since
CBT-SUD+ is easier to implement in substance abuse
treatment centers than I-StoP, it may be concluded from
the above that CBT-SUD+, a CBT treatment addressing
substance use disorders with the inclusion of one sessionaddressing IPV, is a sufficient treatment to treat IPV per-
petration in patients in substance abuse treatment.
Despite the favorable outcome, the results should be
interpreted considering several limitations of the study.
The foremost shortcoming is the high dropout rate
(61.2%), which resulted in a completers sample of only
19 participants. Even though high dropout is common
for patients in substance abuse treatment (a review by
[86] described that the majority of studies reported
dropout rates over 50% in the first month of treatment)
and IPV treatment (ranging from about 20 to 70% [87]),
dropout rates in this study were in the top range. Pre-
sumably, patients in whom both substance abuse and
IPV perpetration are present are even more difficult to
retain in treatment than patients with either problem
alone. Also, dropout rates are comparable to dropout
rates in a similar (pilot) study comparing the effective-
ness of I-StoP to CBT addressing IPV alone among sub-
stance abusing IPV perpetrators referred to outpatient
forensic treatment after committing IPV [Kraanen,
Scholing, Emmelkamp: The comparative effectiveness
of a combined substance abuse–partner violence treat-
ment to partner violence treatment alone among patients
in forensic outpatient treatment: A pilot study, submitted].
We argue however that because this study was conducted
in routine clinical care, these dropout rates accurately
reflect clinical practice, and that the external validity of
this study is probably high. Further, it is also noticeable
that low numbers of dropouts completed question-
naires (49% completed assessment halfway treatment,
39% completed posttreatment assessment), even though
it has been tried repeatedly to obtain data by mailing
questionnaires to patients and phoning them in order
to remind participants to complete the forms. Unfortu-
nately, it is common for patients in substance abuse
treatment that they are difficult to contact after drop-
out, probably because they often suffer from various
psychosocial problems as well.
Further, due to high dropout rates, statistical power
for the completers sample (but not the ITT sample) was
low. As described in the Methods section, 21 partici-
pants per condition were needed to detect a large differ-
ence between groups, tested 1-sided against alpha = .05
for a power of .80. For the ITT analyses, this number of
21 participants per condition was met, but not for the
completers sample. Therefore, it is possible that true
differences among completers (within groups as well as
between groups) were not demonstrated. However, the
main finding of the study is that the frequency of IPV
had dropped to about zero in both treatment conditions
for the patients who finished the treatment, independent
of pretreatment severity of IPV.
Also, dropouts and completers were compared and
were found not to differ regarding pretreatment physical
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juries, days of abstinence, substance use Z-scores, and
pretreatment Axis-I disorders, except for major depres-
sive episode. Chi-square tests demonstrated that drop-
outs were more often diagnosed with major depressive
episode (N = 9; 29.0%) than completers (N = 1; 5.0%) (X2
(1) = 4.45; p = .04). This is in accordance with previous
research; several studies have demonstrated that depres-
sion is linked to early treatment attrition (e.g., [88-90]).
However, the fact that almost no differences were found
between dropouts and completers might also be attribut-
able to low statistical power (i.e., at least 64 or 21 par-
ticipants per condition were necessary to demonstrate
(according to [84]) medium or large effect sizes of
Cohen’s f = .25 and .40, respectively; [83]). For example,
the pretreatment physical IPV scores of completers who
received I-StoP (M = 6.91) were obviously lower than
ITT allocated to I-StoP (M = 12.12). In addition, since
there were fewer patients who reported at least 7 acts of
physical IPV in the past year than we had expected, we
were unable to reach the target of 100 participants
within the period that patients were recruited. Yet, des-
pite the relatively small number of completers, IPV de-
creased significantly in the completers as well as the ITT
sample. Nonetheless, future research should focus on
finding approaches, apart from using motivational
interviewing techniques, to increase treatment adher-
ence and include more participants. For example, by
targeting depressive symptoms from the beginning of
treatment, as suggested by [90]. Also, expectancies re-
garding treatment should be assessed at the beginning
of and during the course of treatment to examine
whether treatments correspond with patients’ expecta-
tions and whether incorrect expectancies may be a rea-
son for dropout.
Related to the high dropout and low retention rates is
the fact that no ‘state of the art’ analyses could be used
to analyze the results, such as multiple imputation (MI).
MI performs well with dropout rates of at most 50% but
power decreases fast as dropout rates get higher [91].
Further, MI demands that data are missing at random
(MAR) (e.g., [92-94]). Many dropouts could not be
contacted, but we assumed that they had probably re-
lapsed and thus were not missing at random (NMAR).
Moreover, the variables to be imputed exceeded the
number of participants and imputing scale scores would
lead to increased standard errors [91]. Since the data
were probably NMAR, multilevel analysis could not be
performed as well [79].
Another point of discussion is that the results were
based on self-report, which may have been influenced
by patients' tendency to underreport IPV perpetration.
Alternative methods would have been using police re-
cords and/or partners reports as outcome. However,police records to verify IPV have a similar problem
since only a small proportion of IPV is reported to the
police (e.g., [95,96]). On the other hand, partner reports
are also subject to limitations. [97] for example even
demonstrated that victims reported less IPV than per-
petrators. We have two reasons to assume that the
findings in this study are fairly reliable and valid. 1) We
tried to obtain pre- and posttreatment measures of
partner on IPV by administering the CTS2. At pretreat-
ment, 40.4% of partners completed the CTS2; at
posttreatment this was only 7.7% of the total sample.
Using these questionnaires as primary outcome measure
would result in even lower completion rates. However,
when comparing CTS2 physical IPV outcomes of both
partners, we found no significant differences between par-
ticipant and partner reports (Z = −0.82; p = .41), with part-
ners reporting less acts of physical IPV (M= 6.5) than
participants (M= 9.0). The second is that not only treat-
ment progress but also study inclusion was based on self-
disclosure of IPV. It is probable that some patients were
not included at all because they underreported IPV, but
the group who was finally included reported at least
enough IPV to meet inclusion criteria. Another limitation
is that the treatments in general lasted significantly longer
than intended (on average 33 instead of 16 weeks). Rea-
sons for this delay were, for example, that therapist and
patient could not schedule sessions during certainweeks,
were on vacation, or because patients were doing so well
that they, in agreement with their therapist, did not need
to come to the institution every week and instead pre-
ferred to spread treatment sessions over a longer period.
This last point possibly implies that a shorter treatment
might also be effective in reducing both substance use and
partner violence. Further, results of the present study ap-
pear promising compared to the results of the meta-
analyses by [31] and [32] that demonstrated that IPV
treatment alone was hardly effective in reducing IPV.
However, the comparison between the current study and
these meta-analyses is difficult; the meta-analyses included
follow-up data (6 months or more) whereas the current
study only reported posttreatment results. Moreover, the
meta-analyses included only police and partner reports
compared to self-report in the present study. Further, al-
though lacking follow-up results are also a limitation of
the study, we argue that posttreatment and follow-up re-
sults are two different research topics that each have
merits of their own. Finally, due to the small completers
sample, it was not possible to add covariates to the ana-
lyses and control, for example, for participants’ own sub-
stance use, partner substance use and IPV victimization
since statistical power would be too low.
The limitations described above lead to the following
suggestions for future research. In the first place, it
would be interesting to study whether a shorter treat-
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effective in reducing IPV perpetration as the 16 ses-
sions counting CBT-SUD+ treatment. Further, since
CBT-SUD+ contains 1 session addressing IPV, a pro-
spective study could compare CBT-SUD+ to substance
abuse treatment without addressing IPV to investigate
whether it is indeed necessary to address IPV to reduce
IPV perpetration or that substance abuse treatment alone
is sufficient. Further, patients receiving inpatient treatment
were excluded from the study. Future research should in-
vestigate whether CBT-SUD+ is as effective in reducing
IPV in inpatients with more severe substance use disor-
ders than in outpatients. In addition, predictors of
treatment success should be studied. For example,
there is substantial evidence that three or four subtypes
of IPV perpetrators could be distinguished, i.e., the
family only perpetrator who is only violent towards the
partner, the borderline / dysphoric IPV perpetrator,
who is characterized by psychic distress and is some-
times violent outside the family, and the antisocial IPV
perpetrator (sometimes divided in two subtypes with
different severity) who commits most extrafamilial vio-
lence of the subtypes [98,99]. It would be relevant to
assess whether subtypes (or other patient characteris-
tics) predict treatment success and/or dropout rates.
Also, it should be examined whether type of substance
use disorder predicts treatment outcome, whereas pre-
vious research only demonstrated that successfully
treating alcohol dependence led to reductions in IPV
perpetration. Although individual patients with alcohol,
cannabis and/or cocaine use disorders who were in-
cluded in the present study had improved with regard to
IPV perpetration at posttreatment, unfortunately, the
number of participants in this study was too low to
analyze patients with different substance use disorders
separately. Finally, it should be studied whether I-StoP is
effective in reducing IPV perpetration in substance abus-
ing patients who are referred to IPV treatment.
Despite its limitations, the study has several strengths.
In the first place, it was demonstrated among patients
entering substance abuse treatment that both treatments
were successful in reducing IPV perpetration. Com-
pleters in both conditions almost did not perpetrate any
IPV 8 weeks before the end of treatment compared to
(on average) about 12 acts of physical IPV in the 8 weeks
before starting treatment. Moreover, results are directly
applicable to clinical practice.
Conclusions
Based on the outcome of the present study we advise to
routinely screen for IPV perpetration at intake, for ex-
ample by using the J-IPV. After screening positive, IPV
should be further assessed with, for instance, the CTS2.
If IPV perpetration is confirmed, patients should beallocated to CBT-SUD+, since CBT-SUD+ is easier to
implement in a substance abuse treatment center and
therapists only need a limited amount of additional
training to carry out the protocol. Moreover, since re-
sults indicated that it is not necessary to refer IPV per-
petrating patients in substance abuse treatment to IPV
treatment, CBT-SUD+ is a cost- and time-effective ap-
proach and it saves patients the inconvenience from at-
tending treatment at two separate institutions. However,
since this is the posttreatment report and effects of I-StoP
may be delayed, follow-up results should be awaited to
draw more firm conclusions regarding the comparative
effectiveness of I-StoP and CBT-SUD+ and effectiveness
of both treatments on the long term.
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